Anna Turkova, Man K Chan, Cissy Kityo, Adeodata R Kekitiinwa, Philippa Musoke, Avy Violari, Ebrahim Variava, Moherndran Archary, Tim R Cressey, Suwalai Chalermpantmetagul, Kanokkorn Sawasdichai, Pradthana Ounchanum, Suparat Kanjanavanit, Sakulrat Srirojana, Ussanee Srirompotong, Steven Welch, Alasdair Bamford, Cristina Epalza, Clàudia Fortuny, Angela Colbers, Eleni Nastouli, Simon Walker, Dan Carr, Magda Conway, Moira J Spyer, Nazia Parkar, Iona White, Alessandra Nardone, Margaret J Thomason, Rashida A Ferrand, Carlo Giaquinto, Deborah Ford
BACKGROUND: There is increasing interest in utilising two-drug regimens for HIV treatment with the goal of reducing toxicity and improve acceptability. The D3 trial evaluates the efficacy and safety of DTG/3TC in children and adolescents and includes a nested pharmacokinetics(PK) substudy for paediatric drug licensing. METHODS: D3 is an ongoing open-label, phase III, 96-week non-inferiority randomised controlled trial(RCT) conducted in South Africa, Spain, Thailand, Uganda and the United Kingdom...
April 16, 2024: Contemporary Clinical Trials